gx_demo_sarah_mitchell_2026
·
47 variants · Generated May 30, 2026
Sarah presents a genetic profile with notable methylation pathway variants (MTHFR C677T homozygous) that explain her slightly elevated homocysteine levels (11.2 μmol/L). Combined with her Hashimoto's thyroiditis and COMT intermediate metabolizer status, a targeted supplementation strategy focusing on methylated B-vitamins, antioxidant support, and thyroid cofactors is recommended.
This is the most clinically significant finding. Homozygous T/T reduces MTHFR enzyme activity by approximately 70%, impairing folate metabolism and methylation capacity. This directly correlates with Sarah's borderline homocysteine of 11.2 μmol/L.
Compound heterozygosity with C677T modestly amplifies the methylation impairment. Current supplement stack addresses this adequately.
Sarah is an intermediate metabolizer for CYP2D6 substrates. This affects metabolism of her PRN lorazepam (minimal CYP2D6 involvement — low concern) but is important for future prescribing decisions.
Intermediate dopamine/norepinephrine clearance. This is consistent with Sarah's managed anxiety — she may be more sensitive to catecholamine fluctuations under stress but has balanced baseline metabolism.
Reduced mitochondrial superoxide dismutase activity increases oxidative stress burden. Combined with Hashimoto's (autoimmune-driven inflammation), targeted antioxidant support is strongly recommended.
This report is for educational and informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting, stopping, or modifying any supplement, medication, or health protocol. Genetic variants are one factor among many — environmental, lifestyle, and clinical context must be considered. Geneius uses peer-reviewed research and clinical guidelines but cannot guarantee outcomes.